First Page | Document Content | |
---|---|---|
![]() Date: 2012-04-08 15:24:08Bevacizumab Ruxolitinib Food and Drug Administration Pharmacology Pharmaceutical sciences Medicine | Add to Reading List |
![]() | SUPPLEMENTARY INFORMATION: Specificity and mechanism-‐ of-‐action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) 1. DeterDocID: 1rQNF - View Document |
![]() | HAEMATOLOGY AUDIT TEMPLATEDocID: 1pL02 - View Document |
![]() | Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, RichardDocID: 19YPO - View Document |
![]() | Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.caDocID: 19fx5 - View Document |
![]() | PDF DocumentDocID: 16gSu - View Document |